About the data
How this atlas is built
Records last refreshed from ClinicalTrials.gov on July 6, 2026.
Who builds this
The atlas is built and maintained by Delfa, a company that builds patient-recruitment infrastructure for clinical trials. The atlas is a public-record project that team compiles and publishes on the GLP-1 and incretin landscape, not an automatically scraped and republished feed; the classifications and site resolution below are ours, and we correct them when they are wrong.
Scope
The atlas covers clinical trials of GLP-1 and related incretin peptide therapeutics (GLP-1, GIP, glucagon and amylin receptor agonists and their combinations) across every indication they are studied in, from obesity and type 2 diabetes to cardiovascular, renal, liver and neurodegenerative disease. Each trial is linked to its drug asset, lead sponsor, study population and recruiting sites.
Sources
Trial records come from ClinicalTrials.gov, the public registry maintained by the U.S. National Library of Medicine. Linked publications come from PubMed. Asset-level facts such as mechanism and route of administration are curated by Delfa from public sources. Nothing in the atlas comes from confidential or paywalled data.
Refresh cadence
The registry is re-ingested on a monthly cycle: new trials entering the field, protocol updates, status changes and newly disclosed sites. The date at the top of this page, and in the footer of every page, is the last completed refresh.
How study populations are classified
Population labels come from the conditions and condition MeSH terms reported for each trial on ClinicalTrials.gov. A deterministic Delfa ruleset groups lexical synonyms under consistent disease headings, removes drug names, biomarkers and other terms that do not describe a study population, and preserves an unmatched condition only when at least two trials share it. Titles and eligibility text are not used to guess a population, and one trial can carry several labels.
These labels organize public registry records; they are not observed patient counts, eligibility conclusions or evidence that a site can recruit a population. A missing label remains unclassified rather than being inferred from the study title.
How sites are placed on the map
Every dot on the site map represents one resolved trial-site entity. A dot can use a verified facility address, a postcode centre or a city centre; its detail panel states which precision tier applies. ClinicalTrials.gov also publishes coordinates for many registered trial locations without stating their precision. The local-study finder keeps those as registry points and labels them separately rather than calling them exact buildings. Some sponsors mask site names; those records remain anonymous, and very close masked locations from the same trial may be grouped. We do not invent an address.
Limits
The atlas inherits the registry's limits: sponsors differ in how quickly and how completely they update their records, so enrollment numbers, statuses and site lists can trail reality. Endpoint groupings and study-population labels are Delfa's classifications of the registry text and can contain errors.
Corrections
Spotted something wrong, like a misplaced site, a misclassified asset, or a trial we're missing? Email luke@delfa.ai and we'll fix it in the next refresh. The atlas is built by Delfa, which builds patient-recruitment infrastructure for clinical trials.